SpinoS

Call Us

(+91422) 4352491

Opening hours

Mon - Sat : 09AM - 05PM

Email

info@spinoslifescience.com

“SpinoS successfully completed the USFDA audit from 08 Aug 22 – 11 Aug 22 with “NIL 483”.

US FDA published new guidance which describes FDA’s compliance policy related to the retention of reserve samples of the test article and reference standard used in an in vivo bioavailability (BA) and in vivo or in vitro bioequivalence (BE) study.

The guidelines mention Minimum Sample Retention Quantities Sufficient for All Agency Testing.

As per the recent guidance from US FDA, minimum quantity of drug product for sample retention proposed with 30 units each of test and reference product for single-dose units and 3 units each of test and reference product in multi-dose units from each shipment for Investigational Medicinal products.

Weblink for downloading the guidance document:
https://www.fda.gov/media/141218/download